News tagged with ipilimumab
Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody developed by Bristol-Myers Squibb, and works by activating the immune system.
Additionally, ipilimumab is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer 16 hours ago | not rated yet | 0
The humanized antibody ipilimumab (trade name Yervoy) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means ...
Cancer Nov 09, 2012 | not rated yet | 0
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.
Cancer Mar 27, 2012 | not rated yet | 0
Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center
Cancer Mar 15, 2012 | 5 / 5 (4) | 0 |
A breakthrough drug that could extend survival in some patients with advanced skin cancer was approved on Wednesday by US regulators, offering the first new treatment for melanoma in 13 years.
Cancer Aug 17, 2011 | 5 / 5 (1) | 0